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Background: Variants in the Methylenetetrahydrofolate reductase (MTHFR) gene may result in a lowered catalytic
activity and associate with subsequent elevated serum homocysteine (Hcy) concentration, abnormal DNA synthesis
and methylation, cardiovascular risk, and unhealthy aging. Several investigations on the relationship of MTHFR
C677T polymorphism with serum lipid profile and longevity have been conducted in some populations, but the
findings remain mixed. Herein, we sought to look at the association between MTHFR C677T and lipid profile in a
longevous cohort in Bama, a well-known home of longevity in China.
Methods: Genotyping of MTHFR C677T was undertaken in 516 long-lived inhabitants (aged 90 and older, long-lived
group, LG) and 493 healthy controls (aged 60–75, non-long-lived group, non-LG) recruited from Bama area. Correlation
between MTHFR genotypes and lipids was then evaluated.
Results: T allele and TT genotype were significantly more prevalent in LG (P = 0.001 and 0.002, respectively), especially
in females, than in non-LG. No difference in the tested lipid measures among MTHFR C677T genotypes was observed
in LG, non-LG and total population (P > 0.05 for all). However, female but not male T carriers exhibited higher TC and
LDL-C levels than did T noncarriers in the total population and in LG after stratification by sex (P < 0.05 for each). These
differences did not however remain through further subdivision by hyperlipidemia and normolipidemia.
Conclusion: The higher prevalence of MTHFR 677 T genotypes and its modest unfavorable impact on lipids in Bama
long-lived individuals may imply an existence of other protective genotypes which require further determination.Introduction
Methylenetetrahydrofolate reductase (MTHFR) cataly-
ses the conversion of 5,10-methylenetetrahydrofolate
to 5-methyltetrahydrofolate, the methyl donor which re-
methylates homocysteine (Hcy) to methionine [1]. Methio-
nine is the immediate precursor of S-adenosylmethionine
(SAM), the universal methyl donor of numerous biological
methylation reactions that are essential to the synthesis
of DNA, proteins, phospholipids and various neuro-
transmitters [2]. Recently, the relation between Hcy and
lipid metabolism has been underpinned, and the proposed* Correspondence: sl.pan.berkeley@gmail.com
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unless otherwise stated.biochemical link between the two is the SAM-dependent
formation of phosphatidylcholine from phosphatidyl-
ethanolamine [3]. Phospholipids are associated with very
low-density lipoprotein assembly, thus affecting the high-
density lipoprotein (HDL) pool [4]. Many studies have
demonstrated that insufficient MTHFR activity confers
higher serum Hcy level which has been increasingly linked
to the pathogenesis of several age-related disorders, such
as inherited thrombophilias [5], ischemic heart disease,
stroke [6], Alzheimer’s disease (AD) [7], cognition impair-
ment [8], and diabetes [9]. The underlying mechanism of
age-related phenotypes under higher Hcy condition may
point to its detrimental damage on vascular endothelial
cells due to uncontrolled lipid peroxidation, enhanced oxi-
dative stress and inflammation [10,11]. Elevated serumtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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main be ascribed to vitamin deficiency (e.g. folate, B12 and
B6), renal dysfunction, aging or a common variance to the
MTHFR gene, in which cytosine is replaced by thymidine
(C > T) at base position 677. This single nucleotide poly-
morphism (rs1801133) causes an alanine-to-valine substi-
tution in the MTHFR protein at polypeptide position 222
that renders the enzyme more thermolabile and less active
as compared to the wild-type enzyme [12].
Collectively, a complex relationship is potentially existed
among Hcy, lipid levels, MTHFR C677T polymorphism,
aging, and ultimately, lifespan. The exploration of the rela-
tion between the MTHFR C677T and lipid profiles in
long-lived individuals may thus help to provide insight
into the biology of human aging and aging-related dis-
eases. However, available literatures from this subfield are
limited and the results are mixed. Bama long-lived indi-
viduals, a unique cohort reside along the midstream of
Hongshuihe River in Guangxi Province, P.R. China, has
emerged as an optimal cohort for human aging/longevity
study in view of its relatively uniform genetic background
over the past decades [13]. We designed the present study
to test the hypothesis that the MTHFR C677T poly-
morphism is associated with different serum lipid profiles
and may partially account for the longevity in Bama nona-
genarians/centenarians of Zhuang ethnic origin.
Materials and methods
Study subjects
We screened common age-related disorders including cor-
onary heart disease (CHD), stroke, hypertension, diabetes,
cancer, gout, asthma, chronic bronchitis and chronic si-
nusitis for 574 nonagenarians/centenarians who have been
physically living in Bama area (Bama, Fengshan, Donglan,
and Du’an County) along the midstream of Hongshuihe
River Basin, Guangxi Zhuang Autonomous Region, the
People’s Republic of China by two experienced physicians
and excluded 58 individuals who were evidently unhealthy
(stroke, n = 16; Parkinson disease, n = 2; hypertension, tak-
ing medication, n = 22; emphysema and chronic bron-
chitis, n = 9; long-term bedridden sufferers of unknown
causes, n = 11). Finally, 516 apparently healthy nonagenar-
ians/centenarians (127 males and 389 females, age 93.23 ±
2.95 and range 90–104 years) were included in this study
(referred to hereafter as the long-lived group or LG). At
the same time, 530 elderly aged 60–75 years without a fa-
milial history of exceptional longevity (no past or current
nonagenarian/centenarian in the first, second and third
degree relatives) from the same geographic region were
also screened for the same spectrum of diseases, 493 of
which (142 males and 351 females, age 67.19 ± 4.70 and
range 60–75 years) were finally recruited as controls (non-
long-lived group, non-LG) and 37 were excluded due to
stroke (n = 2), hypertension (taking medication, n = 14),diabetes (taking medication, n = 3), chronic bronchitis (n = 10)
and heavy alcoholics (n = 8). All subjects under investiga-
tion were unrelated and belong to Zhuang ethnic group,
the China’s largest minority mainly residing in Guangxi.
Approval for the current study was obtained from the
Ethics Committee of Guangxi Medical University. All par-
ticipants gave their written informed consent after an ex-
tensive description of the study aims and design.
Epidemiological survey
Socio-demographic information was obtained using a
standardized questionnaire. Anthropometric measures
including height, weight and waist were measured in all
groups. Body mass index (BMI) was calculated as weight
(kg)/height2 (m). Sitting blood pressure measures (average
of three readings) were collected using a standard mercury
sphygmomanometer with the subject resting for at least
5 minutes before measurement. Systolic blood pressure
was determined by the first Korotkoff sound; and diastolic,
by the fifth Korotkoff sound. Hypertension was defined
as systolic blood pressure > 140 mmHg and/or diastolic
blood pressure > 90 mmHg. Normal weight, overweight,
and obesity were defined as a BMI < 24, 24 to 28, and >
28 kg/m2, respectively [14].
Biochemical measurements
A blood sample of 8 mL was collected by venipuncture
from each subject after an overnight fast of > 8 h, 4 mL
of which was for serum separation and subsequent lipid
determination while the remaining was transferred to an
anticoagulant tube (4.80 g/L citric acid, 14.70 g/L glucose,
and 13.20 g/L trisodium citrate) for DNA isolation. Total
cholesterol (TC), triglycerides (TG), LDL-C and high dens-
ity lipoprotein cholesterol (HDL-C) concentrations were
measured by standard enzymatic methods using commer-
cially available kits (Daiichi Pure Chemicals Co, Ltd.,
Tokyo, Japan) on a biochemical analyzer (Type 7170A;
Hitachi Ltd, Tokyo, Japan) at our Clinical Science Experi-
mental Center. The normal ranges of serum TC, TG,
HDL-C, and LDL-C levels in the Center were 3.10-5.17,
0.56-1.70, 0.91-1.81, and 1.70-3.20 mmol/L, respectively.
The individuals with TC > 5.17 mmol/L and/or TG >
1.70 mmol/L were defined as dyslipidemia [15].
Genotyping
Genomic DNA was isolated from nucleated blood cells
using standard methods [16]. The nt 677 C > T variance
was determined by use of the polymerase chain reaction
(PCR) and HinfI restriction enzyme digestion as de-
scribed by Frosst et al. [17]. Briefly, a 198-bp fragment
in the exon 4 of the MTHFR gene was amplified by
using primers 5'-TGA AGG AGA AGG TGT CTG CGG
GA-3' (forward) and 5'-AGG ACG GTG CGG TGA
GAG TG-3' (reverse) (Sangon Biotech, China). PCR was
Table 1 Subject characteristics
LG (n = 516) non-LG (n = 493) F (t or χ2) P
Age (year) 93.23 ± 2.95 67.19 ± 4.70 104.823 0.000
Male/female 127/389 142/351 2.265 0.132
BMI (kg/m2) 20.40 ± 3.62 21.40 ± 3.11 5.161 0.023
SBP (mmHg) 166.72 ± 27.65 135.87 ± 23.25 1.927 0.165
DBP (mmHg) 89.36 ± 13.58 83.15 ± 11.10 0.931 0.335
TC (mmol/L) 5.15 ± 1.03 4.97 ± 0.96 0.522 0.470
TG (mmol/L) 0.98 (0.48) 0.91 (0.59) 1.979 0.160
HDL-C (mmol/L) 1.60 ± 0.38 1.71 ± 0.41 0.841 0.359
LDL-C (mmol/L) 3.05 ± 0.87 2.73 ± 0.88 0.018 0.892
Dyslipidemia n (%) 261 (50.58) 227 (46.04) 2.078 0.149
Hypertension n (%) 456 (88.37) 231 (46.86) 200.000 0.000
Note: LG, long-lived group; non-LG, non-long-lived group; BMI: body mass
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total
cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol. TG values were presented as median
(interquartile range) while other measures were presented as mean ± SD. The
difference between the two groups was determined by analysis of covariance.
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genomic DNA, 10 μL of 2× Taq MasterMix (Beijing
CoWin Bioscience, China), 6.25 μM (1.0 μL) of each pri-
mer, 5 μL ddH2O and 1 U of DNA polymerase (Takara
Biotechnology, DaLian, China). The mixture was initially
denatured at 94°C for 2 min, followed by 33 cycles of 95°C
30 sec, 61°C 30 sec, and 72°C 30 sec, with a final 7 min
extension at 72°C. The amplified PCR products (13 μL)
were digested with HinfI (5 U) restriction endonuclease
(New England Biolabs, Beijing, China) at 37°C for 4 h,
and the restriction digestion products were separated
on a 3% agarose gel and visualized by ethidium bromide
staining. The mutant allele (677 T) gives HinfI restriction
fragments of 175 bp and 23 bp, whereas the normal allele
(C677), gives a single fragment of 198 bp. To assess geno-
typing reliability, six randomly selected DNA samples
(two for each genotype) were directly sequenced and the
sequencing results were all consistent with that of geno-
typing. Laboratory technicians who performed genotyping
were blinded to clinical and biochemical data.
Statistical analysis
Data were analyzed with the statistical package SPSS
13.0 (SPSS Inc, Chicago, IL). Levels of the quantitative
variables are presented as mean ± SD. Allelic and geno-
typic frequencies were calculated directly. Comparison of
values of general characteristics between study groups and
test for Hardy-Weinberg equilibrium were performed
with the Pearson chi-square test or analysis of covari-
ance (ANCOVA). The statistical evaluation for the
categorical variables was based on the calculation of
the Student t-test. The association between the MTHFR
C677T polymorphism and lipid variables was tested by
ANCOVA. Multiple logistic analyses with stepwise model-
ling were used to evaluate the association of serum lipid
levels with genotypes (CC = 1, CT = 2, TT = 3) and several
environment factors. In all hypothesis tests, two-tailed
values of P < 0.05 were considered statistically significant.
Results
General characteristics and serum lipid levels
The basic demographic, clinical and biochemical data of
long-lived individuals and controls are presented in
Table 1. After adjusting for covariates, BMI was signifi-
cantly lower while the hypertension rate was significantly
higher in LG as compared to non-LG group (P = 0.023
and P < 0.001 respectively). No statistical difference was
observed on other measures between the two groups
(P > 0.05 for all).
MTHFR C677T polymorphism
Allele and genotype frequencies in both LG and non-LG
are described in Table 2. The genotypes within each
group were distributed in accordance with the Hardy-Weinberg equilibrium. The overall prevalence of geno-
types and alleles were significantly different between
the two groups (P = 0.002 and 0.001, respectively), with
T allele and TT genotype presenting more highly in
LG than in non-LG. These differences persist in fe-
males but not in males after sex stratification. In LG,
almost equal genotypic and allelic frequency of MTHFR
C677T was observed between sexes, while in non-
LG, men presented higher T allele and TT genotype
than women.
Genotypes and serum lipid levels
Lipid characteristics of participants by MTHFR genotype
are presented in Table 3. In LG, non-LG and the pooled
population, the difference in the four lipid measures
among MTHFR C677T genotypes did not attain statis-
tical significance under both co-dominant and T-allele
dominant model (CT/TT). However, when sex was
taken into account, T-allele carriers (CT/TT) of females
but not males were found to have significantly greater
level of TC and LDL-C than were non-T carriers (CC) in
the entire population and in LG, indicating a possible det-
rimental nature of the C > T transition at 677 MTHFR in
lipid modulation. Considering that hyperlipidemia may be
more persuasive than lipid level in interpreting the associ-
ation between the lipid metabolism and thrombophilic
phenotypes, we further analyzed the influence of MTHFR
C677T on lipids according to lipid status. Again, no sig-
nificantly different lipid level was observed among the
three genotypes in the hyperlipidemic and normolipi-
demic subgroup of LG and the hyperlipidemic subgroup
of non-LG, with an exception of a moderate lower
TC and lower LDL-C were noted in subjects harboring
Table 2 Distribution of MTHFR C677T genotype and allele in LG and non-LG
Genotype n (%) Allele n (%)
Group N CC CT TT C T
All 1009 700 (69.38) 266 (26.36) 43 (4.26) 1666 (82.56) 352 (17.44)
LG 516 332 (64.34) 159 (30.81) 26 (4.84) 823 (79.75) 209 (20.25)
non-LG 493 368 (74.65) 107 (21.70) 18 (3.65) 843 (85.50) 143 (14.50)
χ2 - 12.639 11.573
P - 0.002 0.001
LG
Male 127 83 (65.35) 35 (27.56) 9 (7.09) 201 (79.13) 53 (20.87)
Female 389 249 (64.01) 124 (31.88) 16 (4.11) 622 (79.95) 156 (20.05)
χ2 - 2.353 0.079
P - 0.308 0.779
non-LG
Male 142 95 (66.90) 38 (26.76) 9 (6.32) 228 (80.28) 56 (19.72)
Female 351 273 (77.78) 69 (19.66) 9 (2.56) 615 (87.61) 87 (12.39)
χ2 - 7.896 8.750
P - 0.019 0.003
Male
LG 127 83 (65.35) 35 (27.56) 9 (7.09) 201 (79.13) 53 (20.87)
non-LG 142 95 (66.90) 38 (26.76) 9 (6.34) 228 (80.28) 56 (19.72)
χ2 - 0.096 0.109
P - 0.953 0.741
Female
LG 389 249 (64.01) 124 (31.88) 16 (4.11) 622 (79.95) 156 (20.05)
non-LG 351 273 (77.78) 69 (19.66) 9 (2.56) 615 (87.61) 87 (12.39)
χ2 - 16.830 15.771
P - 2.22E-4 7.15E-5
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the normolipidemic subgroup of non-LG (p = 0.001 and
0.005, respectively, Table 4).
Correlation between serum lipid parameters and
genotypes
Multiple linear regression analyses showed that TC, TG
and LDL-C were positively while HDL-C was negatively
correlated in the main with age, diastolic blood pressure
and BMI but not with MTHFR C677T genotypes in the
overall population, i.e. the older of age and the higher
of diastolic blood pressure and BMI, the higher of un-
favorable lipids (Table 5). After sex stratification, lipids,
TC and TG in particular, correlated with not only the
above mentioned factors, but also with MTHFR C677T
genotypes in both sexes. When LG and non-LG were
analyzed separately, the correlation between lipids and
MTHFR C677T genotype exist mainly in the females
of LG. These findings are basically in line with that
in Table 1 and Table 3.Discussion
In the present study, the prevalence of MTHFR 677 T
was 17.44% and 14.50% in the combined samples and
control population respectively, with a lower frequency
of TT homozygote (≈4%). These allelic and genotypic
frequencies are close to that of Bai Ku Yao (22.6%)
whereas much lower than that of Guangxi Han Chinese
(39.1%), two neighboring populations we reported re-
cently [18].
It has been noted that the distribution of the T allele vary
substantially across general populations worldwide, with a
north-to-south increase in European continent but a re-
verse gradient in China mainland [19-21]. Zhuang and Bai
Ku Yao are typical aboriginal ethnic groups in Southern
China, our results thus defer somewhat to this pattern.
The underlying mechanism for this great geographical di-
versity remains unclear, adaptation to external conditions
such as climate or nutritional status could be one explan-
ation [22]. Further investigation of gene-gene and gene-
environment interaction might help to determine the
Table 3 Impact of MTHFR C677T on serum lipid levels (mmol/L)
Group Genotype n TC TG HDL-C LDL-C
All
CC 700 5.04 ± 0.97 0.94 (0.52) 1.66 ± 0.39 2.86 ± 0.90
CT 266 5.15 ± 1.01 0.98 (0.53) 1.63 ± 0.39 3.01 ± 0.84
TT 43 4.86 ± 1.31 0.88 (0.41) 1.61 ± 0.46 2.70 ± 0.98
F — 1.099 0.617 0.190 1.537
p — 0.334 0.540 0.827 0.215
CC 700 5.04 ± 0.97 0.94 (0.52) 1.66 ± 0.39 2.86 ± 0.90
CT/TT 309 5.11 ± 1.06 0.96 (0.50) 1.64 ± 0.41 2.97 ± 0.87
F — 0.163 1.335 0.022 0.001
p — 0.686 0.248 0.883 0.974
Male
CC 178 5.00 ± 1.04 0.95 (0.70) 1.61 ± 0.41 2.84 ± 0.96
CT 73 4.78 ± 0.97 0.87 (0.48) 1.59 ± 0.42 2.72 ± 0.83
TT 18 4.70 ± 0.98 0.83 (0.45) 1.68 ± 0.57 2.58 ± 0.73
F — 1.560 2.001 0.477 1.106
p — 0.212 0.137 0.621 0.332
CC 178 5.00 ± 1.04 0.95 (0.70) 1.61 ± 0.41 2.84 ± 0.96
CT/TT 91 4.77 ± 0.97 0.86 (0.46) 1.61 ± 0.45 2.69 ± 0.81
F — 3.042 3.837 0.025 1.830
p — 0.082 0.051 0.876 0.177
Female
CC 522 5.05 ± 0.95 0.93 (0.49) 1.68 ± 0.38 2.87 ± 0.88
CT 193 5.29 ± 0.99 1.02 (0.62) 1.65 ± 0.38 3.12 ± 0.82
TT 25 4.97 ± 1.52 1.01 (0.43) 1.61 ± 0.46 2.79 ± 1.13
F — 3.762 0.452 0.181 4.227
p — 0.024 0.637 0.835 0.015
CC 522 5.05 ± 0.95 0.93 (0.49) 1.68 ± 0.38 2.87 ± 0.88
CT/TT 218 5.26 ± 1.06 1.02 (0.53) 1.65 ± 0.39 3.08 ± 0.86
F — 4.183 0.766 0.232 4.504
p — 0.041 0.382 0.630 0.034
LG
CC 332 5.12 ± 1.00 0.97 (0.49) 1.59 ± 0.37 3.04 ± 0.87
CT 159 5.22 ± 1.06 0.99 (0.50) 1.61 ± 0.38 3.09 ± 0.86
TT 25 5.13 ± 1.31 1.07 (0.44) 1.56 ± 0.51 3.01 ± 0.96
F — 0.148 0.017 0.073 0.305
p — 0.863 0.983 0.930 0.737
CC 332 5.12 ± 1.00 0.97 (0.49) 1.59 ± 0.37 3.04 ± 0.87
CT/TT 184 5.20 ± 1.09 1.00 (0.48) 1.61 ± 0.40 3.08 ± 0.88
F — 0.276 0.003 0.000 0.558
p — 0.600 0.959 0.993 0.456
Male
CC 83 5.00 ± 1.11 0.94 (0.39) 1.57 ± 0.41 2.96 ± 0.95
CT 35 4.67 ± 1.11 0.87 (0.29) 1.54 ± 0.39 2.67 ± 0.97
TT 9 4.71 ± 1.09 0.84 (0.53) 1.55 ± 0.64 2.76 ± 0.77
F — 1.377 0.983 0.081 1.255
p — 0.256 0.377 0.922 0.289
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Table 3 Impact of MTHFR C677T on serum lipid levels (mmol/L) (Continued)
CC 83 5.00 ± 1.11 0.94 (0.39) 1.57 ± 0.41 2.96 ± 0.95
CT/TT 44 4.67 ± 1.09 0.87(0.34) 1.54 ± 0.44 2.69 ± 0.92
F — 2.749 1.398 0.158 2.450
p — 0.100 0.239 0.691 0.120
Female
CC 249 5.15 ± 0.96 0.98 (0.52) 1.60 ± 0.35 3.06 ± 0.84
CT 124 5.37 ± 1.00 1.04 (0.62) 1.63 ± 0.38 3.21 ± 0.80
TT 16 5.37 ± 1.40 1.09 (0.47) 1.56 ± 0.44 3.15 ± 1.05
F — 2.179 2.148 0.605 1.188
p — 0.115 0.113 0.546 0.306
CC 249 5.15 ± 0.96 0.98 (0.52) 1.60 ± 0.35 3.06 ± 0.84
CT/TT 140 5.37 ± 1.04 1.07 (0.61) 1.63 ± 0.38 3.20 ± 0.83
F — 4.366 3.091 0.580 2.307
p — 0.037 0.080 0.447 0.130
Non-LG
CC 368 4.97 ± 0.95 0.91 (0.60) 1.73 ± 0.40 2.70 ± 0.90
CT 107 5.06 ± 0.92 0.95 (0.59) 1.66 ± 0.41 2.90 ± 0.79
TT 18 4.47 ± 1.25 0.85 (0.24) 1.75 ± 0.49 2.28 ± 0.86
F — 4.138 2.135 0.728 4.601
p — 0.017 0.119 0.483 0.010
CC 368 4.97 ± 0.95 0.91 (0.60) 1.73 ± 0.40 2.70 ± 0.90
CT/TT 125 4.98 ± 1.00 0.89 (0.47) 1.68 ± 0.42 2.81 ± 0.83
F — 0.137 1.833 0.032 0.128
p — 0.712 0.176 0.858 0.721
Male
CC 95 4.99 ± 0.99 0.97 (0.91) 1.63 ± 0.41 2.75 ± 0.96
CT 38 4.89 ± 0.83 0.89 (0.70) 1.64 ± 0.45 2.76 ± 0.68
TT 9 4.69 ± 0.92 0.81 (0.49) 1.81 ± 0.49 2.40 ± 0.68
F — 0.677 1.372 1.096 0.963
p — 0.510 0.257 0.337 0.384
CC 95 4.99 ± 0.99 0.97 (0.91) 1.63 ± 0.41 2.75 ± 0.96
CT/TT 47 4.86 ± 0.84 0.85 (0.67) 1.67 ± 0.46 2.69 ± 0.69
F — 0.670 2.637 0.537 0.212
p — 0.415 0.107 0.465 0.646
Female
CC 273 4.96 ± 0.94 0.90 (0.52) 1.76 ± 0.40 2.69 ± 0.88
CT 69 5.15 ± 0.96 1.00 (0.49) 1.68 ± 0.38 2.97 ± 0.84
TT 9 4.26 ± 1.54 0.85 (0.24) 1.70 ± 0.52 2.16 ± 1.05
F — 5.413 1.114 0.820 5.323
p — 0.005 0.330 0.441 0.005
CC 273 4.96 ± 0.94 0.90 (0.52) 1.76 ± 0.40 2.69 ± 0.88
CT/TT 78 5.05 ± 1.07 0.95 (0.40) 1.68 ± 0.40 2.88 ± 0.90
F — 0.287 0.063 1.727 1.594
p — 0.592 0.803 0.190 0.208
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Table 4 Impact of MTHFR C677T on serum lipid levels according to lipid status (mmol/L)
Group Genotype n TC TG HDL-C LDL-C
LG
Dyslipidemia
CC 167 5.84 ± 0.76 1.14 (0.69) 1.68 ± 0.39 3.57 ± 0.74
CT 84 5.96 ± 0.75 1.16 (0.71) 1.70 ± 0.41 3.66 ± 0.70
TT 10 6.30 ± 1.14 1.13 (1.10) 1.72 ± 0.66 3.80 ± 0.89
F — 1.265 0.120 0.501 0.431
p — 0.284 0.887 0.607 0.605
CC 167 5.84 ± 0.76 1.14 (0.69) 1.68 ± 0.39 3.57 ± 0.74
CT/TT 89 5.99 ± 0.81 1.16 (0.72) 1.71 ± 0.44 3.67 ± 0.72
F — 1.001 0.041 0.232 0.625
p — 0.318 0.839 0.631 0.430
Normolipidemia
CC 165 4.38 ± 0.58 0.85 (0.33) 1.51 ± 0.32 2.49 ± 0.62
CT 75 4.38 ± 0.65 0.85 (0.28) 1.51 ± 0.32 2.45 ± 0.52
TT 15 4.35 ± 0.69 0.94 (0.47) 1.45 ± 0.36 2.48 ± 0.57
F — 0.021 0.228 0.240 0.222
p — 0.979 0.796 0.786 0.801
CC 165 4.38 ± 0.58 0.85 (0.33) 1.51 ± 0.32 2.49 ± 0.62
CT/TT 90 4.38 ± 0.65 0.85 (0.34) 1.50 ± 0.33 2.46 ± 0.53
F — 0.029 0.350 0.109 0.149
p — 0.865 0.555 0.742 0.700
Non-LG
Dyslipidemia
CC 168 5.65 ± 0.92 1.16 (0.98) 1.71 ± 0.45 3.19 ± 1.00
CT 53 5.77 ± 0.59 1.11 (1.06) 1.68 ± 0.43 3.43 ± 0.61
TT 6 5.85 ± 0.39 0.85 (0.55) 2.19 ± 0.49 3.12 ± 0.46
F — 0.307 1.270 1.880 0.501
p — 0.736 0.283 0.155 0.606
CC 146 5.71 ± 0.66 1.16 (0.98) 1.71 ± 0.41 3.43 ± 0.64
CT/TT 58 5.76 ± 0.58 1.08 (1.13) 1.70 ± 0.42 3.45 ± 0.58
F — −0.530 −0.443 0.121 −0.148
p — 0.597 0.658 0.903 0.883
Normolipidemia
CC 200 4.40 ± 0.50 0.80 (0.34) 1.74 ± 0.36 2.29 ± 0.52
CT 54 4.36 ± 0.58 0.69 (0.32) 1.65 ± 0.39 2.37 ± 0.56
TT 12 3.79 ± 0.90 0.79 (0.24) 1.53 ± 0.33 1.86 ± 0.70
F — 7.662 0.987 1.272 5.337
p — 0.001 0.374 0.282 0.005
CC 200 4.40 ± 0.50 0.80 (0.34) 1.74 ± 0.36 2.29 ± 0.52
CT/TT 66 4.26 ± 0.68 0.75 (0.33) 1.63 ± 0.38 2.27 ± 0.61
F — 1.478 1.202 1.339 0.156
p — 0.225 0.274 0.248 0.694
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Table 5 Correlation between serum lipid parameters and the MTHFR C677T polymorphism
Group/Lipid Relative factor Unstandardized coefficients Standardized coefficients t P
B Std. error Beta
All
TC DBP 0.010 0.003 0.123 3.802 1.52E-4
BMI 0.035 0.009 0.121 3.794 1.57E-4
Sex 0.207 0.070 0.091 2.960 0.003
Age 0.005 0.002 0.067 2.073 0.038
TG BMI 0.016 0.002 0.265 8.754 8.59E-18
SBP 0.001 0.000 0.094 3.099 0.002
HDL-C Age −0.005 0.001 −0.173 −5.532 4.04E-8
BMI −0.018 0.004 −0.156 −4.992 7.03E-7
Sex 0.068 0.028 0.076 2.437 0.014
LDL-C Age 0.011 0.002 0.169 5.247 1.88E-7
DBP 0.008 0.002 0.115 3.599 3.35E-4
BMI 0.027 0.008 0.102 3.228 0.001
Sex 0.137 0.062 0.068 2.230 0.026
Male
TG BMI 0.010 0.004 0.157 2.593 0.010
Age −0.002 0.001 −0.142 −2.343 0.020
Genotype −0.042 0.020 −0.127 −2.136 0.034
HDL-C BMI −0.029 0.008 −0.225 −3.700 2.62E-4
Age −0.005 0.002 −0.153 −2.522 0.012
Female
TC DBP 0.009 0.003 0.117 3.052 0.002
BMI 0.046 0.011 0.160 4.311 1.85E-5
Age 0.009 0.003 0.118 3.078 0.002
TG BMI 0.019 0.001 0.327 9.317 1.35E-19
Age 0.002 0.001 0.169 4.822 1.73E-6
HDL-C Age −0.005 0.001 −0.183 −5.013 6.71E-7
BMI −0.015 0.004 −0.132 −3.601 3.38E-4
LDL-C Age 0.013 0.002 0.199 5.176 2.94E-7
BMI 0.030 0.009 0.117 3.184 0.002
DBP 0.007 0.003 0.105 2.759 0.006
Genotype 0.139 0.069 0.072 2.006 0.045
LG
TC DBP 0.012 0.003 0.160 3.699 3.40E-4
Sex 0.323 0.103 0.135 3.130 0.002
TG BMI 0.007 0.002 0.160 3.708 2.32E-4
Sex 0.046 0.016 0.120 2.779 0.006
HDL-C BMI −0.015 0.005 −0.145 −3.312 0.001
DBP 0.001 0.001 0.103 2.359 0.019
LDL-C DBP 0.008 0.003 0.124 2.857 0.004
Sex 0.232 0.088 0.115 2.639 0.009
Male
TC DBP 0.015 0.007 0.181 2.056 0.042
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Table 5 Correlation between serum lipid parameters and the MTHFR C677T polymorphism (Continued)
HDL-C BMI −0.026 0.011 −0.217 −2.480 0.014
LDL-C DBP 0.014 0.006 0.200 2.277 0.024
Female
TC DBP 0.011 0.004 0.154 3.072 0.002
Genotype 0.215 0.103 0.104 2.087 0.038
TG BMI 0.029 0.007 0.197 3.974 8.45E-5
Genotype 0.117 0.047 0.124 2.511 0.012
HDL-C Age 0.014 0.006 0.111 2.204 0.028
Non-LG
TC BMI 0.081 0.013 0.263 6.047 2.92E-9
TG BMI 0.097 0.013 0.324 7.598 1.54E-13
HDL-C BMI −0.019 0.006 −0.149 −3.314 0.001
SBP −0.002 0.001 −0.118 −2.636 0.009
Sex 0.084 0.040 0.094 2.133 0.033
LDL-C BMI 0.067 0.013 0.237 5.304 1.72E-7
Age 0.022 0.008 0.120 2.691 0.007
Male
TC BMI 0.061 0.027 0.189 2.307 0.023
Age −0.046 0.020 −0.186 −2.265 0.025
TG Age −0.064 0.021 −0.247 −3.066 0.003
BMI 0.064 0.027 0.188 2.336 0.021
HDL-C BMI −0.033 0.012 −0.222 −2.698 0.008
LDL-C BMI 0.064 0.025 0.212 2.569 0.011
Female
TC BMI 0.087 0.016 0.285 5.553 5.57E-8
TG BMI 0.103 0.014 0.364 7.294 2.03E-12
HDL-C SBP −0.003 0.001 −0.166 −3.126 0.002
BMI −0.015 0.007 −0.121 −2.281 0.023
LDL-C BMI 0.060 0.015 0.216 3.983 8.28E-5
Age 0.029 0.009 0.162 3.093 0.002
DBP 0.012 0.004 0.139 2.632 0.009
Note: DBP, Diastolic blood pressure; SBP, Systolic blood pressure; BMI, Body mass index.
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variant in certain areas and ethnic groups.
Intriguingly, MTHFR 677 T and its relevant genotypes
(CT, TT) were significantly more prevalent in our nona-
genarian and centenarian populations, especially in fe-
males, as compared with the elder control group (60–75
years). These observations implicate a potential associ-
ation between MTHFR C677T polymorphism and lon-
gevity in Bama area. A question of whether this variant
is favorable or deleterious for Bama long-lived individ-
uals therefore emerges. According to most but not all re-
ported data, MTHFR 677 T genotypes have been linked
to unfavorable lipid profiles, including greater concen-
trations of TC, TG, and LDL-C [18,23-25] and lowerlevel of HDL-C [26,27], all known risk factors for cardio-
vascular and metabolic diseases. Herein, the female but
not male T-allele carriers in the pooled population and
in LG presented greater level of TC, TG and LDL-C
than did T noncarriers (Table 3 and Table 5), in agree-
ment with prevailing data as aforementioned, indicating
that MTHFR 677 T genotypes may play detrimental ra-
ther than beneficial role in lipid modulation and sur-
vivorship. However, this influence seems to be limited
because the impact of MTHFR 677 T on lipid metabol-
ism remained only in the normolipidemic subgroup of
non-LG after further analysis according to lipid status
categorization (Table 4). Together, these data suggest
that although MTHFR C677T affects the TC and LDL-C
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varying degree, particularly of the females in LG, these
impacts may not be sufficient to cause extremely lipid
abnormality.
With regard to the enrichment of deleterious geno-
types in long-lived females, it might be partially inter-
preted by the Buffering Mechanisms in Aging hypothesis
proposed recently by Bergman and colleagues who rea-
soned that in a subpopulation endowed with a favorable
longevity genotype(s), the prevalence of a deleterious
genotype is expected not to vary or even increase with age
because the longevity genotype may buffer out or modu-
late the harmful effect of deleterious ones, while in a sub-
population lacking longevity genotypes, the prevalence of a
deleterious genotype will decrease with age since subjects
with this genotype are weeded out due to mortality [28,29].
Therefore, screening for potential longevity genotypes
such as CETP (VV) (rs5882), APOC3 (CC) (rs2542052),
AdipoQ (del/del APM1 + 2019) (rs56354395), and FOXO3a
(GG), which have been demonstrated in other populations
[30-33], will be one of our next efforts in the near future.
Due to the established link among MTHFR C677T poly-
morphism, Hcy, cardiovascular risk and aging, several in-
vestigations have been conducted in some elder cohorts to
look at the possible contribution of MTHFR to longevity.
However, findings are still inconsistent thus far. For in-
stance, lower frequency of MTHFR C677T +/+genotype,
with raised Hcy level, was observed in French cohort
with longevity trait (> 90 yrs, n = 564) than in controls
(< 70 yrs, n = 374), albeit no statistical significance was
reached [34]. Similar observations were made in Swiss
(106 elderly, 68–95 yrs vs 118 younger, 21–64 yrs) [35],
Japanese (148 oldest, > 80 yrs including 22 nonagenarians
vs 311 younger, < 55 yrs) [36] and Jerusalem Ashkenazi
(224 elderly, > 75 yrs vs 441 controls, < 22 yrs) [37] popu-
lations, while almost equal prevalence of MTHFR C677T
genotypes were seen between elderly and younger group
in Swede (222 elderly, 80–108 yrs vs 220 newborn) [38],
British (282 elderly, > 84 yrs vs 200 younger, < 17 yrs)
[39], and Jordanian (130 elderly, > 85 yrs, mean age
90.01 yrs vs 135 younger, 20–50 yrs, mean age 33.34 yrs)
[40] population. Conversely, we detected a higher preva-
lence of MTHFR 677 T in our oldest olds. Although it is
known that MTHFR TT might be a risk biomarker against
longevity from other perspectives, we cannot exclude the
possibility that it may also be in favor of good health or
long life span as implicated by Le Marchand et al. that
there might be an inverse association between MTHFR
677TT genotype and the development of colorectal cancer
[41]. To the best of our knowledge, the nonagenarian
population here is the only long-lived cohort that en-
riches this variant, whose significance deserves further
clarification. These discrepancies may arise from factors re-
lated to differences in ethnic background of the populationstudied, recruitment strategy for long-lived and control
group, assessment methods or sample sizes.
Despite strengths such as large sample size, highly
population genetic homogeneity and well-characterized
cases and controls, all the difference of lipid profiles be-
tween long-lived individuals and controls cannot com-
pletely attribute to MTHFR C677T. The current study
should be viewed in the light of some limitations: (1) no
determination of folate status, serum MTHFR activity
and Hcy levels on baseline data collection due to insuffi-
cient funding, which would be more significantly conclu-
sive and would help to interpret the selection and the
outcome of MTHFR 677 T [22,42]; (2) lack of the evalu-
ation of other modifying genetic variants, risk factors
such as smoking and alcohol consumption and lifestyle
which may interact with MTHFR C677T and change its
association with longevity; (3) we could not completely
exclude asymptomatic disorders such as atherosclerosis
which may create a potentially significant bias due to
poor field study condition; (4) it is very much speculative
to imagine the controls would have a short life span be-
cause of a specific family history, this may also be a signifi-
cant bias factor. (5) longitudinal follow up is warranted in
further interpreting the potential effect of MTHFR C677T
polymorphism on lipid metabolism.
Conclusions
Overall, our results show that MTHFR 677 T allele and
TT genotype are accumulative in Bama long-living indi-
viduals in a gender-specific manner and are associated
with unfavorable lipid profile although this impact on
lipid modulation seems limited. Potential longevity gene(s)
which may interact with or buffer out the deleterious effect
of this variant needs to be determined.
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